Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Healios KK Ord Shs HLOSF

Healthcare Biotechnology
Healios KK is a Japan-based company mainly engaged in business in the somatic stem cell regenerative medicine field and in the iPSC regenerative medicine field, which involves research, development and manufacture of regenerative medicine products (iPSC regenerative medicines) utilizing technologies related to induced pluripotent stem cells (iPS cells, iPSCs). The somatic stem cell regenerative medicine field develops and markets cell therapy drugs for acute stroke and acute respiratory distress syndrome using MultiStem, a somatic stem cell product for which the Company holds patent and patent licensing rights. The iPSC regenerative medicines include the creation of universal donor cells (UD), next-generation iPSCs that reduce the risk of immune rejection regardless of human leukocyte antigen (HLA) type using gene editing technology.


PINL:HLOSF - Post by User

Healios KK Ord Shs > Selling Pressure All "Anonymous"
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by Crazy_Hendersonon Jan 27, 2011 12:08pm
360 Views
Post# 18034879

RE: Selling Pressure All "Anonymous"

RE: Selling Pressure All "Anonymous"

Category

Mining

Tonnes

Copper

Zinc

Gold

Silver

Method

(Mllbs)

(Mllbs)

(ozs)

(ozs)

Indicated

Open Pit

5,317,000

94

144

58,829

1,233,373

Underground

1,235,800

28

32

19,230

325,343

Total Indicated

6,552,800

122

176

78,059

1,558,716

Inferred

Open Pit

12,240,000

168

208

103,921

2,083,390

Underground

3,620,000

72

87

37,324

857,689

Total Inferred

15,860,000

240

294

141,245

2,941,079

I can't believe I can buy a company with a cap of 7mil that has:

240 mil pounds copper
294 mil pounds of zinc
141,245 oz of gold
2,941,079 oz of silver

All near surface, infrastructure in mining friendly Manitoba. 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities